Accessibility Menu
 
VYNE Therapeutics logo

VYNE Therapeutics

(NASDAQ) VYNE

Current Price$0.68
Market Cap$22.54M
Since IPO (2020)-100%
5 Year-99%
1 Year-45%
1 Month+11%

VYNE Therapeutics Financials at a Glance

Market Cap

$22.54M

Revenue (TTM)

$454.00K

Net Income (TTM)

$21.46M

EPS (TTM)

$-0.53

P/E Ratio

-1.27

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$0.68

Volume

0

Open

$0.68

Previous Close

$0.68

Daily Range

$0.67 - $0.68

52-Week Range

$0.28 - $1.96

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About VYNE Therapeutics

Industry

Pharmaceuticals

Employees

10

CEO

David Domzalski

Headquarters

Bridgewater, NJ 08807, US

VYNE Financials

Key Financial Metrics (TTM)

Gross Margin

98%

Operating Margin

-54%

Net Income Margin

-47%

Return on Equity

-63%

Return on Capital

-99%

Return on Assets

-83%

Earnings Yield

-78.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.54M

Shares Outstanding

33.32M

Volume

0

Avg. Volume

201.79K

Financials (TTM)

Gross Profit

$547.00K

Operating Income

$29.75M

EBITDA

$26.73M

Operating Cash Flow

$33.12M

Capital Expenditure

$0.00

Free Cash Flow

$33.12M

Cash & ST Invst.

$29.01M

Total Debt

$0.00

VYNE Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$86.00K

-57.4%

Gross Profit

$80.00K

-60.4%

Gross Margin

93.02%

N/A

Market Cap

$22.54M

N/A

Market Cap/Employee

$1.73M

N/A

Employees

13

N/A

Net Income

$3.58M

+58.4%

EBITDA

$3.58M

+61.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$24.93M

-50.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-82.93%

N/A

Return on Invested Capital

-98.91%

N/A

Free Cash Flow

$4.08M

+64.4%

Operating Cash Flow

$4.08M

+64.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCLIBrainstorm Cell Therapeutics Inc.
$0.72+4.35%
XTLBXTL Biopharmaceuticals Ltd.
$2.53-6.40%
TCRTAlaunos Therapeutics, Inc.
$2.47+0.40%
KTTAPasithea Therapeutics Corp.
$0.70-9.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.28-0.06%
POETPoet Technologies
$12.10-0.15%
NOWLGraniteShares ETF Trust - GraniteShares 2x Long Now Daily ETF
$5.49+0.06%
INTCIntel
$104.24-0.04%

Questions About VYNE

What is the current price of VYNE Therapeutics?

VYNE Therapeutics is trading at $0.68 per share.

What is the 52-week range for VYNE Therapeutics?

Over the past 52 weeks, VYNE Therapeutics has traded between $0.28 and $1.96.

How much debt does VYNE Therapeutics have?

As of the most recent reporting period, VYNE Therapeutics reported total debt of N/A.

How much cash does VYNE Therapeutics have on hand?

VYNE Therapeutics reported $24.63M in cash and cash equivalents in its most recent financial results.

What is VYNE Therapeutics’s dividend yield?

VYNE Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.